Risk-stratification Based Bladder-sparing Modalities for Muscle-invasive Bladder Cancer

Neoadjuvant chemotherapy plus radical cystectomy is the standard if care for cisplatin-eligible patients with MIBC. Developments in the last two decades suggest that bladder sparing therapy may be a valuable alternative to radical cystectomy. Currently, well-documented TMT regimens, which include complete transurethral resection of bladder tumor (TURBT), chemotherapy, and radiation therapy, demonstrated durable oncologic control and long-term survival in selected patients. Nevertheless, TMT has not been widely used in clinical practice. On the one hand, due to the complexity of TMT, multiple c

Trial Details

NCT ID
NCT05531123
Phase
PHASE2
Sponsor
Fudan University
Status
RECRUITING
Cancer Type
Urothelial Carcinoma Bladder Cancer
Interventions
  • Tislelizumab
  • gemcitabine and cisplatin
  • Modified hypofractionation
Locations (sample)
  • Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

  • Male or female aged 18 and ≤ 85;
  • People who want to protect their bladder;
  • ECOG PS 0 2 points;
  • Subject underwent TURBT surgery and imaging diagnosis of musculothelial invasive bladder urothelial carcinoma (histologic variation accepted, not d…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Urothelial Carcinoma Bladder Cancer Trials on Trialify →